Investment Summary

ArchiMed Invests In Title21

On July 12, 2022, private equity firm ArchiMed invested in software company Title21

Investment Highlights
  • This is ArchiMed’s 2nd transaction in the Software sector.
  • This is ArchiMed’s 6th transaction in the United States.
  • This is ArchiMed’s 1st transaction in Arizona.

Investment Summary
Date 2022-07-12
Target Title21
Sector Software
Investor(s) ArchiMed
Deal Type Growth Capital

Target

Title21

Phoenix, Arizona, United States
Title21 is a provider of paperless electronic services to cell & gene therapy labs. Title21’s clients include globally preeminent hospital and research institutions, including the Mayo Clinic, Memorial Sloan Kettering Cancer Center, Stanford University, Kaiser Permanente, and the University of Pennsylvania Health System. The fast-growing cell & gene therapy industry is transforming the treatment of life-threatening conditions including genetic disorders like spinal muscular atrophy, and diseases caused by vital infection, including COVID-19. Title21 was formed in 2001 and is based in Pleasanton, California.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

ArchiMed

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2014
PE ASSETS 8.0B EUR
Size Mega
Type Sector Focused
DESCRIPTION

ArchiMed is a specialist French private equity firm focused on buyouts of and growth capital investments in European healthcare-oriented companies. The Firm looks to invest €10 million to €1 billion per transaction and specifically targets companies in the public health, care and wellness, biotech, and medical technology segments of the healthcare industry. ArchiMed was formed in 2014 and is headquartered in Lyon.

DEAL STATS #
Overall 30 of 36
Sector (Software) 2 of 2
Type (Growth Capital) 6 of 7
State (Arizona) 1 of 1
Country (United States) 6 of 9
Year (2022) 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-24 Corealis Pharma

Laval, Quebec, Canada

Corealis Pharma is a provider of formulation development and clinical supply manufacturing. The company offers a spectrum of R&D services focused exclusively on pharmaceutical oral solid dosage forms (i.e. tablets, capsules, and granules) and Current Good Manufacturing Practices (cGMP) services for phase I, II and to a lesser extent, early phase III studies. COREALIS has R&D laboratories, cGMP laboratories, and phase I, II, and early phase III clinical trial manufacturing packaging suits. Corealis Pharma was founded in 2005 and is based in Laval, Quebec.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-07-21 Natus

Middleton, Wisconsin, United States

Natus is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Natus was founded in 1987 and is based in Pleasanton, California.

Buy $1.1B
Mergr

Product

Company

Legal